AI Market Mood: Stock Dashboard
XAIR
Fundamental
Company: Beyond Air Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -7.53
Insider Own: 5.88%
Shs Outstand: 8.01M
Perf Week: -3.36%
Market Cap: 12.11M
Forward P/E: -
EPS next Y: -2.06
Insider Trans: 0.00%
Shs Float: 7.54M
Perf Month: 38.72%
Enterprise Value: 13.41M
PEG: -
EPS next Q: -0.75
Inst Own: 18.31%
Short Float: 32.30%
Perf Quarter: -38.83%
Income: -36.70M
P/S: 2.09
EPS this Y: 72.16%
Inst Trans: -4.23%
Short Ratio: 0.33
Perf Half Y: -59.51%
Sales: 5.80M
P/B: 0.72
EPS next Y Percentage: 46.31%
ROA: -87.40%
Short Interest: 2.44M
Perf YTD: 58.40%
Book/sh: 1.59
P/C: 1.12
EPS next 5Y: 73.05%
ROE: -179.63%
52W High: 10.40 -88.94%
Perf Year: -85.26%
Cash/sh: 1.03
P/FCF: -
EPS past 3/5Y: 25.75% 17.29%
ROIC: -152.16%
52W Low: 0.67 70.80%
Perf 3Y: -99.13%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - 21.66%
Gross Margin: -6.69%
Volatility W: 9.70%
Volatility M: 19.15%
Perf 5Y: -99.03%
Dividend TTM: -
EV/Sales: 2.31
EPS Y/Y TTM: 73.23%
Oper. Margin: -575.72%
ATR (14): 0.20
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 3.73
Sales Y/Y TTM: 147.74%
Profit Margin: -632.51%
RSI (14): 45.70
Recom: 1.50
Dividend Gr. 3/5Y: - -
Current Ratio: 4.24
EPS Q/Q: 77.97%
SMA20: -19.28%
Beta: 0.40
Target Price: 10.33
Payout: -
Debt/Eq: 0.93
Sales Q/Q: 127.82%
SMA50: -1.35%
Rel Volume: 0.04
Prev Close: 1.04
Employees: 61
LT Debt/Eq: 0.89
Earnings: Feb 13 BMO
SMA200: -53.66%
Avg Volume: 7.38M
Price: 1.15
IPO: Sep 23, 2016
Option/Short: No / Yes
EPS/Sales Surpr.: -61.64% -15.27%
Trades:
Volume: 328,949
Change: 10.05%
Technical:
Latest News:
New AI drug discovery powerhouse Xaira rises with $1B in funding - Fierce Biotech very bullish
XAIR
Summary: Xaira Therapeutics has emerged with $1 billion in committed funding and an impressive team led by prominent figures in the biotech industry, including Marc Tessier-Lavigne, Ph.D., and David Baker, Ph.D. The company aims to revolutionize drug discovery by combining machine learning, data generation, and therapeutic product development.
Full article2024-04-24T14:00:06Z